Monsenso A/S announced that in collaboration with leading researchers and the pharmaceutical industry, the PhaseV innovation project will set new standards for how the effects of treatment can be documented so that patients are offered the right treatment. Patients and healthcare professionals will thus provide data that can help shed light on whether the treatment is working when Monsenso's digital platform is used to support decentralised trials in the project. The new PhaseV (Phase five) innovation project, in which Innovation Fund Denmark is investing DKK 24 million (of which DKK 8,3 million goes to Monsenso), aims to develop and validate a scalable digital platform for efficient, decentralised patient recruitment, patient data collection and study execution.

This is done by engaging patients and clinicians in the monitoring of treatment effects over longer periods of time based on patients' own feedback, digital biomarkers from smartphones and wearables, as well as registry data. Severe obesity, urticaria and diabetic foot ulcers: The PhaseV project will develop a platform with three apps to collect data on patients with severe obesity, diabetic foot ulcers and urticaria - all of which are costly chronic conditions. For example, annual treatment costs for severe obesity alone are estimated to exceed DKK 15 billion for Danish municipalities and regions.

More than 800,000 Danes live with severe obesity, and associated diseases are very common. As severe obesity causes both direct and indirect costs to society, there is a significant need for good and well-documented weight loss treatments, says Jens Meldgaard Bruun, clinical professor at Aarhus University and Steno Diabetes Center Aarhus and part of PhaseV. Urticaria affects 15-20 percent of the population, and in about 1% it occurs chronically and causes a severely reduced quality of life.

Thorough monitoring and efficient data collection on symptom development are crucial for correct and effective future treatment, says Simon Francis Thomsen, Professor and Chief Physician at Bispebjerg Hospital. 22.000 Danes live with diabetic foot ulcers and treatment costs society more than DKK 5 billion annually. The PhaseV project is expected to bring value to patients, regions, and municipalities, as well as to the institutions and companies involved.